Establishment of a method for evaluating endothelium-dependent hyperpolarization by concurrent use of FMD and RH-PAT accompanying brachial arterial administration of L-NMMA acetate and bradykinin acetate: a pilot study.

Establishment of a method for evaluating endothelium-dependent hyperpolarization by concurrent use of FMD and RH-PAT accompanying brachial arterial administration of L-NMMA acetate and bradykinin acetate: a pilot study. - Establishment of a method for evaluating endothelium-dependent hyperpolarization by concurrent use of FMD and RH-PAT accompanying brachial arterial administration of L-NMMA acetate and bradykinin acetate: a pilot study.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026075

Enrollment

Registered

2017-02-15

Start date

2017-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Not applicable.

Interventions

(1)486 mg of aspirin is taken once orally. (2)0.3 mg of nitroglycerin is taken once orally. (3)L-NMMA acetate is administered at 8 micromol/min for 5 minutes from the brachial artery once. (4)Brad

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy subjects

Exclusion criteria

Exclusion criteria: (1) Those with coronary risk factors (smoking history, hypertension, dyslipidemia, hyperuricemia, diabetes) (2) Those who take medications such as nitrites and calcium channel blockers. (3) Obesity, emaciation (body mass index: less than 18.5, greater than 25) (4) Those who have resting systolic blood pressure less than 100 mmHg or greather than 200 mmHg at the time of measurement of vascular endothelial function (5) Those with arrhythmia such as atrial fibrillation (6) Persons who have had aspirin asthma (7) Others who judged that your doctor is inappropriate for participation in research (8) Women who are pregnant, have a possibility of pregnancy, are within 28 days of childbirth, or who are breastfeeding (9) Those who are judged to be difficult to participate in the trial by merging psychosis or psychiatric symptoms

Design outcomes

Primary

Measure	Time frame
Any adverse events during the examination.	—

Countries

Japan

Contacts

Public ContactShoko Kajitani

Tohoku University Graduate School of Medicine Department of Cardiovascular Medicine

edh-factor@cardio.med.tohoku.ac.jp0227177153

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026